PL2542584T3 - Sposoby leczenia nowotworu trzustki - Google Patents

Sposoby leczenia nowotworu trzustki

Info

Publication number: PL2542584T3
Authority: PL; Poland
Prior art keywords: methods; pancreatic cancer; treating pancreatic; treating; cancer
Prior art date: 2010-01-08

Application number

PL11700115T

Other languages

English (en)

Inventor

Leïla HOUHOU

Dominique Joubert

Frédéric HOLLANDE

Original Assignee

Progastrine Et Cancers S.À R.L.

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Centre National De La Recherche Scientifique (Cnrs)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-08

Filing date

2011-01-07

Publication date

2018-04-30

2011-01-07 Application filed by Progastrine Et Cancers S.À R.L., Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National De La Recherche Scientifique (Cnrs) filed Critical Progastrine Et Cancers S.À R.L.

2018-04-30 Publication of PL2542584T3 publication Critical patent/PL2542584T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Food Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL11700115T 2010-01-08 2011-01-07 Sposoby leczenia nowotworu trzustki PL2542584T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29361210P	2010-01-08	2010-01-08
EP11700115.6A EP2542584B8 (en)	2010-01-08	2011-01-07	Methods for treating pancreatic cancer
PCT/EP2011/000049 WO2011083091A2 (en)	2010-01-08	2011-01-07	Methods for treating pancreatic cancer

Publications (1)

Publication Number	Publication Date
PL2542584T3 true PL2542584T3 (pl)	2018-04-30

Family

ID=43607948

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL11700068T PL2542583T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu piersi
PL11700115T PL2542584T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu trzustki

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL11700068T PL2542583T3 (pl)	2010-01-08	2011-01-07	Sposoby leczenia nowotworu piersi

Country Status (15)

Country	Link
US (2)	US8900588B2 (pl)
EP (2)	EP2542584B8 (pl)
JP (2)	JP5572718B2 (pl)
KR (2)	KR101438362B1 (pl)
CN (2)	CN102892784B (pl)
AU (2)	AU2011204653B2 (pl)
BR (2)	BR112012016742A2 (pl)
CA (2)	CA2786435C (pl)
EA (2)	EA023722B1 (pl)
ES (2)	ES2657245T3 (pl)
NZ (2)	NZ601588A (pl)
PL (2)	PL2542583T3 (pl)
SG (2)	SG182331A1 (pl)
WO (2)	WO2011083091A2 (pl)
ZA (2)	ZA201205004B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
US7854932B2 (en)	2006-12-19	2010-12-21	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
KR101576174B1 (ko) *	2010-07-26	2015-12-09	르 라보레또레 쎄르비에르	간암 요법을 위한 방법 및 조성물
EP4477269A3 (en)	2015-09-20	2025-03-19	The United States of America, as Represented By the Secretary, Department of Health and Human Services	Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
KR102620651B1 (ko) *	2015-12-31	2024-01-04	신케레스 에스.에이 알.엘.	암 발생의 위험도를 평가하기 위한 조성물 및 방법
BR112018013272A2 (en)	2015-12-31	2018-12-11	Progastrine Et Cancers S.À R.L.	compositions and methods for detecting and treating esophageal cancer
ES3011729T3 (en) *	2015-12-31	2025-04-08	Ecs Progastrin Sa	Compositions and methods for detecting and treating gastric cancer
CN108780091A (zh) *	2015-12-31	2018-11-09	普莱戈斯瑞恩癌症有限责任公司	用于检测和治疗卵巢癌的组合物和方法
ES2932262T3 (es) *	2017-01-06	2023-01-17	Lemonex Inc	Composición para la prevención o el tratamiento de cáncer de ovario metastásico, cáncer de endometrio o cáncer de mama
CN110678753B (zh) *	2017-03-30	2023-10-24	普莱戈斯瑞恩癌症有限责任公司	用于治疗肺癌的组合物和方法
SG11201908998XA (en)	2017-03-30	2019-10-30	Progastrine Et Cancers S A R L	Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
IL271427B2 (en) *	2017-06-15	2025-08-01	Cancer Advances Inc	Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US11267881B2 (en)	2017-09-14	2022-03-08	Charles ROSSER	Compositions and methods for treatment of diseases involving CXCL1 function
DK3720879T3 (da) *	2017-12-05	2022-06-20	Progastrine Et Cancers S A R L	Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en)	2017-12-08	2020-12-17	Ecs-Biotracker Sàrl	Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh)	2018-01-26	2019-10-16	瑞士商Ｅｃｓ前胃泌激素公司	在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en)	2018-02-27	2021-01-06	ECS-Progastrin SA	Progastrin as a biomarker for immunotherapy
EP3765521A4 (en) *	2018-03-13	2022-03-23	Phanes Therapeutics, Inc.	ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
CN108864255B (zh) *	2018-06-21	2022-01-04	天津医科大学肿瘤医院	一种乳腺癌干细胞特异性结合多肽及其在制备治疗乳腺癌药物中的应用
CA3127943A1 (en)	2019-01-28	2020-08-06	Charles J. Rosser	Compositions and methods for treatment of diseases involving cxcl1 function

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5922845A (en) *	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6548066B1 (en)	1997-05-12	2003-04-15	Aphton Corporation	Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
AU2001241710B2 (en)	2000-02-25	2005-07-21	The Regents Of The University Of California	Membrane estrogen receptor-directed therapy in breast cancer
FR2846426B1 (fr)	2002-10-28	2004-12-10	Bio Merieux	Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
EP2567974A3 (en)	2004-09-22	2013-05-22	Cancer Advances, Inc.,	Monoclonal antibodies to progastrin
PL2040753T3 (pl) *	2006-05-22	2019-09-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibitory progastryny w leczeniu raka okrężnicy
JPWO2008032876A1 (ja)	2006-09-15	2010-01-28	学校法人東海大学	Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
WO2008063479A2 (en)	2006-11-17	2008-05-29	Fred Hutchinson Cancer Research Center	Pancreatic cancer biomarkers
US7854932B2 (en)	2006-12-19	2010-12-21	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
US20120052061A1 (en)	2007-09-24	2012-03-01	Tragara Pharmaceuticals Inc.	Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
RS57966B1 (sr) *	2009-10-16	2019-01-31	Progastrine Et Cancers S A R L	Monoklonska antitela na progastrin i njihova upotreba

2011
- 2011-01-04 US US12/984,509 patent/US8900588B2/en not_active Expired - Fee Related
- 2011-01-04 US US12/984,522 patent/US9487582B2/en not_active Expired - Fee Related
- 2011-01-07 ES ES11700068.7T patent/ES2657245T3/es active Active
- 2011-01-07 CA CA2786435A patent/CA2786435C/en not_active Expired - Fee Related
- 2011-01-07 ES ES11700115.6T patent/ES2657246T3/es active Active
- 2011-01-07 SG SG2012049136A patent/SG182331A1/en unknown
- 2011-01-07 EP EP11700115.6A patent/EP2542584B8/en active Active
- 2011-01-07 CN CN201180013038.7A patent/CN102892784B/zh not_active Expired - Fee Related
- 2011-01-07 BR BR112012016742-1A patent/BR112012016742A2/en not_active Application Discontinuation
- 2011-01-07 CN CN201180013036.8A patent/CN102933603B/zh not_active Expired - Fee Related
- 2011-01-07 KR KR1020127020835A patent/KR101438362B1/ko not_active Expired - Fee Related
- 2011-01-07 WO PCT/EP2011/000049 patent/WO2011083091A2/en not_active Ceased
- 2011-01-07 NZ NZ601588A patent/NZ601588A/en not_active IP Right Cessation
- 2011-01-07 EA EA201200998A patent/EA023722B1/ru not_active IP Right Cessation
- 2011-01-07 AU AU2011204653A patent/AU2011204653B2/en not_active Ceased
- 2011-01-07 PL PL11700068T patent/PL2542583T3/pl unknown
- 2011-01-07 EP EP11700068.7A patent/EP2542583B8/en active Active
- 2011-01-07 EA EA201200999A patent/EA025329B1/ru not_active IP Right Cessation
- 2011-01-07 CA CA2786479A patent/CA2786479C/en not_active Expired - Fee Related
- 2011-01-07 WO PCT/EP2011/000048 patent/WO2011083090A2/en not_active Ceased
- 2011-01-07 KR KR1020127020871A patent/KR101468397B1/ko not_active Expired - Fee Related
- 2011-01-07 AU AU2011204654A patent/AU2011204654B2/en not_active Ceased
- 2011-01-07 PL PL11700115T patent/PL2542584T3/pl unknown
- 2011-01-07 JP JP2012547494A patent/JP5572718B2/ja not_active Expired - Fee Related
- 2011-01-07 NZ NZ601591A patent/NZ601591A/en not_active IP Right Cessation
- 2011-01-07 SG SG2012049177A patent/SG182334A1/en unknown
- 2011-01-07 JP JP2012547495A patent/JP6134141B2/ja not_active Expired - Fee Related
- 2011-01-07 BR BR112012016820A patent/BR112012016820A2/pt not_active IP Right Cessation
2012
- 2012-07-04 ZA ZA2012/05004A patent/ZA201205004B/en unknown
- 2012-07-04 ZA ZA2012/05003A patent/ZA201205003B/en unknown

Also Published As

Publication number	Publication date
CA2786479C (en)	2016-03-15
EA201200999A1 (ru)	2013-02-28
EA201200998A1 (ru)	2013-02-28
BR112012016742A2 (en)	2018-05-15
US8900588B2 (en)	2014-12-02
EP2542584B8 (en)	2017-12-13
WO2011083091A2 (en)	2011-07-14
ZA201205003B (en)	2013-09-25
EA025329B1 (ru)	2016-12-30
US20110177062A1 (en)	2011-07-21
CN102933603A (zh)	2013-02-13
EP2542583A2 (en)	2013-01-09
NZ601591A (en)	2015-01-30
US9487582B2 (en)	2016-11-08
CN102892784B (zh)	2016-06-22
SG182334A1 (en)	2012-08-30
CA2786435C (en)	2017-01-17
WO2011083090A2 (en)	2011-07-14
AU2011204654A1 (en)	2012-07-26
EA023722B1 (ru)	2016-07-29
PL2542583T3 (pl)	2018-04-30
AU2011204653B2 (en)	2014-04-10
JP2013516439A (ja)	2013-05-13
CN102892784A (zh)	2013-01-23
EP2542583B1 (en)	2017-10-25
US20110171213A1 (en)	2011-07-14
AU2011204654B2 (en)	2014-04-10
EP2542584B1 (en)	2017-10-25
BR112012016820A2 (pt)	2023-11-28
KR20130028050A (ko)	2013-03-18
JP2013516438A (ja)	2013-05-13
WO2011083091A8 (en)	2012-08-09
CA2786435A1 (en)	2011-07-14
ES2657245T3 (es)	2018-03-02
ES2657246T3 (es)	2018-03-02
CN102933603B (zh)	2016-01-20
WO2011083090A3 (en)	2011-10-06
WO2011083091A3 (en)	2011-09-09
KR20120135401A (ko)	2012-12-13
NZ601588A (en)	2014-07-25
CA2786479A1 (en)	2011-07-14
ZA201205004B (en)	2013-09-25
KR101438362B1 (ko)	2014-09-05
SG182331A1 (en)	2012-08-30
JP5572718B2 (ja)	2014-08-13
EP2542584A2 (en)	2013-01-09
KR101468397B1 (ko)	2014-12-04
JP6134141B2 (ja)	2017-05-24
AU2011204653A1 (en)	2012-07-26
EP2542583B8 (en)	2017-12-13

Publication	Publication Date	Title
IL276362A (en)	2020-08-31	Cancer treatment methods
ZA201205004B (en)	2013-09-25	Methods for treating pancreatic cancer
IL223189A0 (en)	2013-02-03	Methods of treatment of pancreatic cancer
IL227429A0 (en)	2013-09-30	The components and methods of cancer treatment
PL2542585T3 (pl)	2018-04-30	Sposoby leczenia nowotworu jelita grubego
PL3967315T3 (pl)	2025-10-20	Akkermansia muciniphila do leczenia nowotworu złośliwego
EP2734207A4 (en)	2015-06-17	NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
SI3412687T1 (sl)	2020-07-31	Postopek zdravljenja DLBCL
IL228644A0 (en)	2013-12-31	Cancer treatment methods
SG10201500124VA (en)	2015-03-30	Methods and Compositions for Treating Cancer
EP2643001A4 (en)	2014-02-19	METHOD OF TREATING CANCER
ZA201304225B (en)	2018-05-30	Methods of treating cancer
IL225623A0 (en)	2013-06-27	Psoriasis treatment methods
HRP20160851T1 (hr)	2016-09-23	Prediktori za liječenje karcinoma
EP2640390A4 (en)	2014-08-06	METHODS OF TREATING CANCER
ZA201404798B (en)	2020-07-29	Method for treating breast cancer
IL229231A0 (en)	2014-01-30	Preparations and methods for the treatment of cancer
IL218230A0 (en)	2012-04-30	Method of treating cancer
PL2608802T3 (pl)	2017-08-31	Immunoterapeutyczny sposób leczenia raka gruczołu krokowego
EP2560648A4 (en)	2013-10-02	METHOD OF TREATING PANCREATIC CANCER
PT2509599E (pt)	2014-10-15	Processo para o tratamento de cancro pancreático
EP2593100A4 (en)	2014-01-01	METHOD OF TREATING REFRACTORY CANCER
GB201220901D0 (en)	2013-01-02	CD44v6-derived peptides for treating pancreatic cancer
EP2538944A4 (en)	2013-08-28	METHOD FOR TREATING BRAIN TUMORS
EP2707011A4 (en)	2014-11-19	METHOD FOR THE TREATMENT OF PROSTATE CANCER